| Literature DB >> 25063943 |
Joan Albert1, Ramon Bosque2, Margarita Crespo2, Graciela García3, Jaume Granell2, Concepción López4, María Victoria Lovelle3, Romana Qadir3, Asensio González5, Anusha Jayaraman6, Enric Mila6, Roldán Cortés6, Josefina Quirante5, Carme Calvis7, Ramon Messeguer7, Josefa Badía8, Laura Baldomà8, Marta Cascante9.
Abstract
Twelve cyclometallated palladium(II) complexes containing primary aromatic amines [benzylamine (a), (R)-1-(1-naphthyl)ethylamine (b) and 2-phenylaniline (c)] as anionic bidentate (C,N)(-) ligands have been evaluated against a panel of human adenocarcinoma cell lines (A549 lung, MDA-MB231 and MCF7 breast, and the cisplatin resistant HCT116 colon). The results revealed a remarkable antiproliferative activity of the triphenylphosphane mononuclear compounds 3-4 (series a, b, c) and the best inhibition was provided for 3c and 4c with the 2-phenylaniline ligand and a six membered chelate ring. Interestingly, 3c and 4c were 14 and 19 times more potent than cisplatin for the inhibition of the cisplatin resistant HCT116 human adenocarcinoma cell line, respectively. Cyclopalladated complexes 3c and 4c exercise their antiproliferative activity over A549 cells mainly through the induction of apoptosis (38 and 31-fold increase in early apoptotic cells, respectively).Entities:
Keywords: Anticancer drugs; Cyclopalladated complexes; Cytotoxicity; Palladium(II)
Mesh:
Substances:
Year: 2014 PMID: 25063943 DOI: 10.1016/j.ejmech.2014.07.046
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514